We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Gene-Editing Tool Specifically Modifies RNA

By LabMedica International staff writers
Posted on 27 Mar 2018
A team of genomics researchers has isolated and characterized a novel form of the CRISPR gene editing system that specifically targets RNA rather than DNA.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. More...
CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

Investigators at the Salk Institute for Biological Research (La Jolla, CA, USA) analyzed prokaryotic genome and metagenome sequences to identify uncharacterized families of RNA-guided, RNA-targeting CRISPR systems. Biochemical characterization and protein engineering of seven distinct orthologs generated a ribonuclease effector (CasRx) derived from the gut bacterium Ruminococcus flavefaciens XPD3002 with robust activity in human cells. CasRx-mediated knockdown exhibited high efficiency and specificity relative to RNA interference across diverse endogenous transcripts. In addition to high efficiency and specificity, CasRx was one of the most compact single-effector Cas enzymes and could be flexibly packaged into an adeno-associated virus for in in vivo delivery.

To demonstrate the potential clinical value of the CasRx system, the investigators used a viral vector to insert it into neuronal stem cells derived from a patient with the neurodegenerative disorder frontotemporal dementia (FTD). This disorder is characterized by an imbalance in the ratio of two forms of the tau protein. The inserted CasRx had been genetically engineered to target RNA sequences for the version of the tau protein that was in excess.

Results published in the March 15, 2018, online edition of the journal Cell revealed that CasRx was 80% effective in rebalancing the levels of tau protein to healthy levels.

"Bioengineers are like nature's detectives, searching for clues in patterns of DNA to help solve the mysteries of genetic diseases," said senior author Dr. Patrick Hsu, a Helmsley-Salk Fellow at the Salk Institute for Biological Research. "CRISPR has revolutionized genome engineering, and we wanted to expand the toolbox from DNA to RNA."

Related Links:
Salk Institute for Biological Research


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
STI Test
REALQUALITY RQ-SevenSTI
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.